TVRD

Company Overview — What Does Cara Therapeutics, Inc. Do?

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Cara Therapeutics, Inc. (TVRD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher Posner and employs approximately 80 people, headquartered in Shelton, Connecticut. With a market capitalization of $28M, TVRD is one of the notable companies in the Healthcare sector.

Cara Therapeutics, Inc. (TVRD) Stock Rating — Avoid (April 2026)

As of April 2026, Cara Therapeutics, Inc. receives a Avoid rating with a composite score of 23.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TVRD ranks #4,036 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cara Therapeutics, Inc. ranks #704 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TVRD Stock Price and 52-Week Range

Cara Therapeutics, Inc. (TVRD) currently trades at $2.90. The stock lost $0.06 (2.0%) in the most recent trading session. The 52-week high for TVRD is $43.65, which means the stock is currently trading -93.4% from its annual peak. The 52-week low is $3.40, putting the stock -14.7% above its annual trough. Recent trading volume was 51K shares, suggesting relatively thin trading activity.

Is TVRD Overvalued or Undervalued? — Valuation Analysis

Cara Therapeutics, Inc. (TVRD) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.28x, versus the sector average of 2.75x. The price-to-sales ratio is 5.22x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cara Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cara Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Cara Therapeutics, Inc. (TVRD) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -89.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -58.4% versus the sector average of -33.1%.

On a margin basis, Cara Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -92.9% (sector: -66.1%). Net profit margin stands at -191.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TVRD Debt, Balance Sheet, and Financial Health

Cara Therapeutics, Inc. has a debt-to-equity ratio of 53.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.86x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $21M.

TVRD has a beta of -1.21, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Cara Therapeutics, Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cara Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cara Therapeutics, Inc. reported revenue of $5M and earnings per share (EPS) of $-2.46. Net income for the quarter was $-19M. Gross margin was 100.0%. Operating income came in at $-23M.

In FY 2025, Cara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.46. Net income for the quarter was $-18M. Operating income came in at $-27M.

In Q3 2025, Cara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.59. Net income for the quarter was $-6M. Operating income came in at $-6M.

In Q2 2025, Cara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $0.51. Net income for the quarter was $4M. Operating income came in at $-9M.

Over the past 8 quarters, Cara Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $991,000 to $5M. Investors analyzing TVRD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TVRD Dividend Yield and Income Analysis

Cara Therapeutics, Inc. (TVRD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TVRD Momentum and Technical Analysis Profile

Cara Therapeutics, Inc. (TVRD) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

TVRD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cara Therapeutics, Inc. (TVRD) ranks #704 out of 838 stocks based on the Blank Capital composite score. This places TVRD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TVRD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TVRD vs S&P 500 (SPY) comparison to assess how Cara Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TVRD Next Earnings Date

No upcoming earnings date has been announced for Cara Therapeutics, Inc. (TVRD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TVRD? — Investment Thesis Summary

The quantitative profile for Cara Therapeutics, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 16/100, a headwind for near-term performance. High volatility (stability score 37/100) increases portfolio risk.

In summary, Cara Therapeutics, Inc. (TVRD) earns a Avoid rating with a composite score of 23.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TVRD stock.

Related Resources for TVRD Investors

Explore more research and tools: TVRD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TVRD head-to-head with peers: TVRD vs AZN, TVRD vs SLGL, TVRD vs VMD.